Pyxis Oncology, Inc. November 21, 2022 Via Email Only pconnealy@pyxisoncology.com Ms. Pamela Connealy RE: AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Dear Ms. Connealy: On behalf of Pyxis Oncology, Inc. (“Pyxis”, or the “Company”), it is my...Executive Employment Agreement • March 22nd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein.
Pyxis Oncology, Inc. November 21, 2022 Via Email Only jwadhane@pyxisoncology.com RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Mr. Wadhane:Employment Agreement • March 22nd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”) memorializes the employment terms offered to you by Pyxis Oncology, Inc. (“Pyxis” or the “Company”). This Agreement (including all amended and restated terms herein) will supersede and replace in full the prior Offer Letter, entered into by and between you and the Company dated August 10th, 2021 (the “Prior Letter”), and it will become effective as of November 21st, 2022. This Agreement is intended to summarize the terms and conditions of your continued employment with Pyxis.
AMENDMENT NO. 1Pyxis Oncology, Inc. • March 22nd, 2023 • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (“Amendment No. 1”) is made and entered into on June 28, 2022 (the “Amendment Effective Date”), by and between Pyxis Oncology, Inc., a corporation, organized under the laws of Delaware, with its registered office at 35 Cambridgepark Drive, Suite 100-R, Cambridge, MA 02140 (hereinafter referred to as “Pyxis” or “Client”) and Biosion USA, Inc., a Delaware corporation, having an address at 1 Innovation Way, Suite 300, Newark, Delaware 19711 (hereinafter referred to as “Biosion”) and amends that certain March 28, 2022 License Agreement entered into by and between Pyxis and Biosion (the “Agreement”).
AMENDMENT NO. 3 TO LICENSE AGREEMENT THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT (“Amendment No. 3”) is made andLicense Agreement • March 22nd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations
WHEREAS, Pyxis and Biosion entered into that certain License Agreement effective as of March 28, 2022, as further amended by Amendment No. 1 on June 28, 2022, and Amendment No. 2 on July 1, 2022 (collectively, the “Agreement”), pursuant to which Pyxis obtained from Biosion exclusive rights to certain anti-Siglec-15 patents, technology, know-how, and other proprietary materials in the Field in the Licensed Territory (each defined in the Agreement);
AMENDMENT #2 TO LICENSE AGREEMENTLicense Agreement • March 22nd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations
This AMENDMENT #2 TO LICENSE AGREEMENT (this “Amendment”) is made effective as of July 1, 2022 (“Amendment Effective Date”), by and between Pyxis Oncology, Inc., a Delaware corporation, having an address at 35 Cambridge Park Drive, Cambridge, Massachusetts 02140 (“Licensee”), and Biosion USA, Inc., a Delaware corporation, having an address at 1 Innovation Way, Suite 300, Newark, Delaware 19711 (“Licensor”). Licensee and Licensor may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
Amendment No. 1 to Amended and Restated License Agreement (“Amendment No. 1”)License Agreement • March 22nd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations
Name of Original Agreement: Amended and Restated License Agreement, as by that certain Letter Agreement, dated October 14, 2022, between the Parties (the “Agreement”)
